Bioventix Share Discussion Threads

[doctor888] 16/11/2021 18:12

Less interested market means less buyers and sellers and less liquidity. Could also be the usual market maker shenanigans.

[stepone68] 16/11/2021 17:26

Igbert - I've not looked at the note, but is the comparative issue related to the additional 700k revenue from a couple of years ago which was backdated?

Jim - don't know, sorry.

[jimboyce] 16/11/2021 15:57

Why is the spread increasing?

[igbertsponk] 11/11/2021 16:15

Though Note 7 of the accounts needs a bit of work! Comparative total is somewhat out. OOPS!

[igbertsponk] 11/11/2021 16:11

They don't waste oodles on such presentation nonsense. They bill customers, spend a very little on costs and distribute the vast majority of sales revenue as dividends. And have done for eons now. Best run company on the exchange.

[jonut] 11/11/2021 16:02

Full list of bvxp rns's here,

[gnnmartin] 11/11/2021 15:44

I hoped to find the latest BVXP presentation to investors, but I can't find anything later that 2019. I expected to find it on the BVXP web site, but that gives surprisingly little information.

Can anyone tell me where I can find what I seek?

[nigeldoug1] 23/10/2021 11:33

SP seems to be finding a floor mainly around yield. Finncap with a 4300 target....that would be nice.?

[piedro] 21/10/2021 17:02

FWIW ...



- last 6 months recovery confirmed

IMHO.

[stepone68] 20/10/2021 10:57

I do think a buyout will happen here eventually. And if it happens anywhere over £30 I'll be happy enough, with my initial buy at £6 and a top up at 17. It would obviously be a bit disappointing, but hopefully we have time to collect a few dividends between now and then :-)

[vprt] 20/10/2021 10:41

stepone68: Thanks for the clarification/confirmation. The question you are asking is puzzling; I'd be interested if anyone has thoughts on this (especially the company, obviously). Perhaps there already are provisions in the existing contract for after 2032 (in case any production is requested), or perhaps not?

[a1samu] 20/10/2021 10:24

This will drop all the way to £30, at which time someone (Chinese) will make an offer for the company.

[suetballs] 20/10/2021 09:05

Mistimed my buy here - loss now 12% and can't see much short term upside.
May bail and put more into Shell.
Suet

[doctor888] 20/10/2021 07:02

For the 9 month comparison of FY2021 to FY2020, Roche core lab diagnostics increased 26% so plenty of demand and more to come as we get on top of COVID.

[vprt] 19/10/2021 17:50

You're welcome; great if you get full clarity on this point - please share if you do.

[stepone68] 19/10/2021 16:15

Thanks for the link - very interesting. Might drop them a line.

[vprt] 19/10/2021 15:47

stepone68:

There might be better info than I have about the Troponin deal. Anything definitive from the company itself would trump what I have. The following comments are taken from Maynard Paton's website (recommended!) and his analysis of the INTERIMS:
hxxps://maynardpaton.com/2021/04/09/bioventix-h1-revenue-up-just-1-to-outpace-wider-ivd-market-as-rd-efforts-narrow-focus-and-p-e-stays-an-elevated-32x/

In his analysis, towards the end (in a bulleted paragraph about "downsides" he writes:
“Profit advances for the next few years resting almost entirely on the popularity of troponin, the income from which will expire during 2032;”

Then in the Q&A at the bottom of the page (scroll all the way down):
"My understanding is the troponin revenue stream will terminate during summer 2032 and will be zero thereafter. At least that was the message given by the chief exec during this ShareSoc webinar (available to ShareSoc members only; question asked at c50mins). The chief exec said the troponin expiry “does underline the need for us to develop new things that have value in 2025-2035.”

[stepone68] 19/10/2021 13:26

I suppose the key thing is that there is 1.2m of revenue which will not be in future results. Troponin is roughly half of that level. Even if it doubles again this year, we will be down overall, so we need Vitamin D to return to growth.

There are a lot of things I like about this company - the long royalty terms, the simple results, the low cost of sales, being in the healthcare sector, the dividend and the quick dividend turn around time (ex divi next week and paid 2 weeks later). But it is highly rated so I think share price growth will be limited from here on (unless Troponin really takes off).

[stepone68] 19/10/2021 13:11

Hi vprt - do you have a link to your information on the Toponin deal?

[vprt] 19/10/2021 09:54

The main thing that has stopped me from buying is that Troponin is the big growth hope, but it is not owned and permanent, it is just a contract - admittedly a very long contract (2031, if memory serves?) but as a long term investor I don't like that the expiry (a big cliff edge if Troponin is successful) will loom larger and larger over time.

I love management's frankness about rabbit and synthetics, but long term these threats also add to my unease about paying a big multiple today. (But will keep watching)

[shouldhavesold] 19/10/2021 09:34

That’s daft. It’s the yield on current price that’s the only thing worth considering
Otherwise how do you compare with alternatives for your money etc.
You could have an investment 50yrs old paying 5000% on your purchase price - means nothing if it’s 1% on the current value
Compare like with like
Look to the future, not the past

The yield here is good though

[apad] 18/10/2021 14:01

I paid 3854p for BVXP this morning.
Averaging up, so my yield will reduce 😊

My thinking was that I expected them to be suffering more than they are and previously they have been marked down on opening only to recover as folks find something to be pleased about.

Anyroadup they are 3910 to buy at the moment, so not much of an effect.

apad

BTW I have also observed them being marked down on the ex div morning and then ambling up during the day.

[trident5] 18/10/2021 13:50

18% yield is having your cake and eating it though.

[stepone68] 18/10/2021 13:36

It's fine to talk about yield on your purchase price but you should also value your holding at that price. Otherwise you are trying to have your cake and eat it.